Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 74

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 74
---
 technology or other intellectual property we use in a product based on the product's achievement of commercial milestones specified therein.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of financial condition and results of operations is based on our interim condensed consolidated financial statements, that we prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Preparing these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses, and related disclosures. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our accompanying condensed consolidated financial statements, refer to Item 7 in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 10-K. Since December 31, 2024, there have been no material changes to our critical accounting policies or the methodologies or assumptions we apply under them.

36

Results of Operations

Comparison of Three Months Ended June 30, 2025 and 2024 (Unaudited)

The following table summarizes our condensed consolidated results of operations for the periods indicated, together with the changes in those items in terms of dollars and percentage:

Three Months Ended June 30,Change20252024$%Revenues:Royalty revenue$(21,172)$22,438 $(43,610)(194)%Total revenue(21,172)22,438 (43,610)(194)%Operating expenses:General and administrative 2,377,866 2,448,130 (70,264)(3)%Research and development 1,428,762 4,933,774 (3,505,012)(71)%Total operating expenses3,806,628 7,381,904 (3,575,276)(48)%Loss from operations(3,827,800)(7,359,466)3,531,666 (48)%Other income (expense)Sale of royalty and milestone rights, net— 20,379,376 (20,379,376)(100)%Other expense, net(188,683)(109,254)(79,429)73 %